References
- Reaven G. M., Lithell H., Landsberg L. Hypertension and Associated Metabolic Abnormalities—The Role of Insulin Resistance and the Sympathoadrenal System. N Engl Journal of Medicine 1996; 334: 374–381
- Kennedy A., Gettys T. W., Watson P., et al. The Metabolic Significance of Leptin in Humans: Gender-Based Differences in Relationship to Adiposity, Insulin Sensitivity, and Energy Expenditure. J Clin Endocrinol Metab 1997; 82: 1293–1300
- Shek E. W., Brands M. W., Hall J. E. Chronic Leptin Infusion Increases Arterial Pressure. Hypertension 1998; 31(part 2)409–414
- Haynes W. G., Morgan D. A., Walsh S. A., et al. Receptor-mediated Regional Sympathetic Nerve Activation by Leptin. J. Clin. Invest. 1997; 100: 270–278
- Dunbar J. X., Hu Y., Lu H. Intracerebroventricular Leptin Increases Lumbar and Renal Sympathetic Nerve Activity and Blood Pressure in Normal Rats. Diabetes 1997; 46: 2040–2043
- Agata J., Masuda A., Takada M., et al. High Plasma Immunoreactive Leptin Level in Essential Hypertension. Am J Hypertens 1997; 10: 1171–1174
- Modan M., Halkin H., Almog S., et al. Hyperinsulinemia: a link between hypertension, obesity, and glucose tolerance. J Clin Invest 1985; 75: 809–817
- Nilsson P. M., Lind L., Andersson P. E., et al. On the use of ambulatory blood pressure recordings and insulin sensitivity measurements in support of the insulin-hypertension hypothesis. J Hypertens 1994; 12(8)965–969
- Kamide K., Rakugi H., Nakano N., et al. Insulin Resistance Is Related to Silent Cerebral Infarction in Patients With Essential Hypertension. Am J Hypertens 1997; 10: 1245–1249
- Lind L., Berne C., Andersson P. E., et al. Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment?. Journal of Human Hypertension 1995; 9: 759–763
- Weir M. R., Reisin E., Falkner B., et al. Nocturnal Reduction of Blood Pressure and the Antihypertensive Response to a Diuretic or Angiotensin Converting Enzyme Inhibitor in Obese Hypertensive Patients. Am J Hypertens 1998; 11: 914–920
- Reisin E., Weir M. R., Falkner B., et al. Lisinopril Versus Hydrochlorothiazide in Hypertensive Patients A Multicenter Placebo-Controlled Trial. Hypertension 1997; 30(part 1)140–145
- Lithell H. O. Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism. Diabetes Care 1991; 14: 203–209
- Lithell H. O. Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. Journal of Hypertension 1997; 15(suppl 1)S39–S42
- Grimm R. H., Flack J. M., Grandits G. A., et al. Long-term Effects on Plasma Lipids of Diet and Drugs to Treat Hypertension. JAMA 1996; 275: 1549–1556
- Bönner G., Schmieder R., Chrosch R., Weidinger G. Effect of Bunazosin and Atenolol on Glucose Metabolism in Obese Nondiabetic Patients with Primary Hypertension. Cardiovasc Drugs Ther 1997; 11: 21–26
- Morel Y., Gadient A., Keller U., et al. Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol. Journal of Cardiovascular Pharmacology 1995; 26: 306–311
- Suzuki M., Dcebuchi M., Yokota C., et al. Normalization of Insulin Resistance in Non-Obese Essential Hypertension by Cilazapril Treatment. Clin. and Exper. Hypertension 1995; 17(8)1257–1268
- Böhlen L., Bienz R., Doser M., et al. Metabolic Neutrality of Perindopnl: Focus on Insulin Sensitivity in Overweight Patients with Essential Hypertension. Journal of Cardiovascular Pharmacology 1996; 27: 770–776
- Reaven G. M., Clinkingbeard C., Jeppesen J., et al. Comparison of the Hemodynamic and Metabolic Effects of Low-Dose Hydrochlorothiazide and Lisinopril Treatment in Obese Patients with High Blood Pressure. Am J Hypertens 1995; 8: 461–466
- Nilsson P. New drugs and clinical trials in diabetes and hypertension. Exp Clin Endocrinol Diabetes 1997; 105(suppl 2)
- Ogihara T., Rakugi H., Ikegami H., et al. Enhancement of Insulin Sensitivity by Tyroglitazone Lowers Blood Pressure in Diabetic Hypertensives. AJHMar 1995; 8: p316–320
- Hansson L., Zanchetti A., Carruthers S. G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762